How has been the historical performance of Akums Drugs?
Akums Drugs experienced significant fluctuations in financial performance over the past three years, with a notable recovery in FY 2025, reporting net sales of 4,118.16 crore and a profit after tax of 343.78 crore, up from a loss the previous year. Key improvements included a rise in operating profit to 516.61 crore and a substantial increase in earnings per share to 22.09.
Answer:The historical performance of Akums Drugs shows significant fluctuations in key financial metrics over the past three years, culminating in a notable recovery in the fiscal year ending March 2025.Breakdown:
In the fiscal year ending March 2025, Akums Drugs reported net sales of 4,118.16 crore, a slight decrease from 4,178.18 crore in March 2024, but an increase from 3,654.82 crore in March 2023. The total operating income mirrored this trend, remaining stable at 4,118.16 crore in March 2025. The total expenditure, excluding depreciation, decreased to 3,653.67 crore from 4,055.20 crore in the previous year, contributing to a significant rise in operating profit (PBDIT) to 516.61 crore, compared to 157.01 crore in March 2024 and 384.06 crore in March 2023. Profit before tax turned positive at 345.25 crore in March 2025, recovering from a loss of 45.28 crore in March 2024, while profit after tax surged to 343.78 crore, up from just 0.79 crore the previous year. The consolidated net profit also reflected this recovery, reaching 338.18 crore, compared to a loss of 4.04 crore in March 2024. The company's earnings per share (EPS) improved significantly to 22.09 in March 2025, compared to -0.28 in March 2024. On the balance sheet, total assets increased to 3,905.38 crore in March 2025 from 3,393.30 crore in March 2024, while total liabilities also rose to 3,905.38 crore, reflecting a shift from long-term borrowings of 491.56 crore in the previous year to zero in March 2025. Cash flow from operating activities showed a robust increase to 498 crore in March 2024, up from 176 crore in March 2023, indicating improved operational efficiency and cash generation capabilities.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
